Wei Spencer C, Levine Jacob H, Cogdill Alexandria P, Zhao Yang, Anang Nana-Ama A S, Andrews Miles C, Sharma Padmanee, Wang Jing, Wargo Jennifer A, Pe'er Dana, Allison James P
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Computational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065, USA.
Cell. 2017 Sep 7;170(6):1120-1133.e17. doi: 10.1016/j.cell.2017.07.024. Epub 2017 Aug 10.
Immune-checkpoint blockade is able to achieve durable responses in a subset of patients; however, we lack a satisfying comprehension of the underlying mechanisms of anti-CTLA-4- and anti-PD-1-induced tumor rejection. To address these issues, we utilized mass cytometry to comprehensively profile the effects of checkpoint blockade on tumor immune infiltrates in human melanoma and murine tumor models. These analyses reveal a spectrum of tumor-infiltrating T cell populations that are highly similar between tumor models and indicate that checkpoint blockade targets only specific subsets of tumor-infiltrating T cell populations. Anti-PD-1 predominantly induces the expansion of specific tumor-infiltrating exhausted-like CD8 T cell subsets. In contrast, anti-CTLA-4 induces the expansion of an ICOS Th1-like CD4 effector population in addition to engaging specific subsets of exhausted-like CD8 T cells. Thus, our findings indicate that anti-CTLA-4 and anti-PD-1 checkpoint-blockade-induced immune responses are driven by distinct cellular mechanisms.
免疫检查点阻断能够在一部分患者中实现持久反应;然而,我们对抗CTLA-4和抗PD-1诱导肿瘤排斥反应的潜在机制缺乏令人满意的理解。为了解决这些问题,我们利用质谱流式细胞术全面分析了检查点阻断对人黑色素瘤和小鼠肿瘤模型中肿瘤免疫浸润的影响。这些分析揭示了一系列肿瘤浸润性T细胞群体,它们在肿瘤模型之间高度相似,并表明检查点阻断仅靶向肿瘤浸润性T细胞群体的特定亚群。抗PD-1主要诱导特定肿瘤浸润性耗竭样CD8 T细胞亚群的扩增。相比之下,抗CTLA-4除了作用于特定亚群的耗竭样CD8 T细胞外,还诱导ICOS Th1样CD4效应细胞群体的扩增。因此,我们的研究结果表明,抗CTLA-4和抗PD-1检查点阻断诱导的免疫反应是由不同的细胞机制驱动的。